Brief: Yumanity Therapeutics Announces Positive Top-Line Results Of Phase 1B Clinical Trial For Ytx-7739 In Patients With Parkinson’S Disease Company Plans To Advance Program To Phase 2

Kineta

10/11/2021 12:09

Nov 10 (Reuters) - Yumanity Therapeutics Inc  YMTX.O :
    * YUMANITY THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS
OF
PHASE 1B CLINICAL TRIAL FOR YTX-7739 IN PATIENTS WITH
PARKINSON’S DISEASE; COMPANY PLANS TO ADVANCE PROGRAM TO PHASE 2
    * YUMANITY THERAPEUTICS INC - YTX-7739 DEMONSTRATED TARGET
ENGAGEMENT IN PHASE 1B CLINICAL TRIAL IN PATIENTS WITH
MILD-TO-MODERATE PARKINSON'S DISEASE
    * YUMANITY THERAPEUTICS INC - YTX-7739 FOUND TO BE GENERALLY
WELL
TOLERATED
    * YUMANITY THERAPEUTICS INC - YTX-7739 WAS GENERALLY WELL
TOLERATED WITH ALL TREATMENT EMERGENT ADVERSE EVENTS BEING MILD
TO MODERATE IN SEVERITY
    * YUMANITY THERAPEUTICS INC - THERE WERE NO SERIOUS ADVERSE
EVENTS

Source text for Eikon:  ID:nGNX1zd6VQ 
Further company coverage:  YMTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))